PT-141
Also known as: Bremelanotide, Vyleesi
Overview
A melanocortin receptor agonist FDA-approved for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. It acts through the central nervous system rather than directly on vascular tissue.
Benefits
- ✓sexual desire enhancement
- ✓libido support
- ✓arousal function
Potential Side Effects
- •nausea
- •flushing
- •injection site reactions
- •headache
- •nasal congestion (nasal form)
- •temporary increase in blood pressure
Who Should Avoid
- ⚠pregnancy or breastfeeding
- ⚠uncontrolled hypertension or cardiovascular disease
- ⚠hypersensitivity to bremelanotide
- ⚠history of melanoma or suspicious skin lesions
Interactions & Precautions
May interact with blood pressure medications. Can cause transient increases in blood pressure and heart rate. Comprehensive cardiovascular assessment recommended. Avoid use within 24 hours of alcohol consumption.
Dosing Information from Literature
FDA-approved dosing is 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity, no more than one dose in 24 hours or 8 doses per month.
This is descriptive information only. Always consult a licensed healthcare provider for dosing guidance.
Storage
Store unreconstituted peptide in freezer (-20°C or colder). After reconstitution with bacteriostatic water, store refrigerated and use within 2-3 weeks. FDA-approved product comes pre-filled.